Sungjune Kim, MD, PhD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses phase II study findings on the safety and tolerability of nivolumab/ipilimumab plus stereotactic body radiation therapy (Abstract 1321P).
Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyond hormone receptor status in HER2-positive early breast cancer (Abstract 248P).
Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses study findings from the first phase III trial to show PD-1 and CTLA-4 inhibition is effective in non–small cell lung cancer, with improved overall survival vs chemotherapy (Abstract LBA4).
Thomas Powles, MD, PhD, of Queen Mary University of London, discusses the first study to examine immunotherapy and targeted treatment combinations with a personalized approach in bladder cancer. FGF, TORC1/2, and PARP inhibitors were explored in combination with durvalumab in selected patients (Abstract 902O).
Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre at the University of Melbourne, and Leisha A. Emens, MD, PhD, of UPMC Hillman Cancer Center, discuss overall survival in this phase II study of atezolizumab/trastuzumab emtansine (T-DM1) vs placebo/T-DM1 in previously treated HER2-positive advanced breast cancer (Abstract 305O).
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses long-term outcomes from a phase II trial which showed that nivolumab/ipilimumab therapy demonstrated durable intracranial responses in patients with melanoma brain metastases. No new adverse events were reported (Abstract 1311O).
